Video Hero Poster

Enhancing critical medicines

Learn More

ADVANZ PHARMA is a specialty pharmaceutical company with a strategic focus on complex medicines in Europe that is committed to improving the lives of patients by enhancing the critical medicines they depend on.

We could not do this without the resilience and entrepreneurial spirit of our people, the successful collaboration with our partners, and intrinsic guidance of our values to help us achieve our purpose while becoming a truly dynamic, progressive company in the process.

Our portfolio —

At ADVANZ PHARMA, our European hospital portfolio of complex medicines focuses on Anti-infectives, Endocrinology and Critical Care medicines.

This is bolstered by an established brands business unit of more than 180 molecules sold into 100 countries across a wide range of therapy areas such as CVD, pain management, ophthalmology, urology, and central nervous system disorders.

Careers & Culture —

The success of any company is driven by its people. We are no different. Our teams are made up of people who come from all walks of life and backgrounds, and thrive in an environment where diversity is celebrated but where we are all united by the same passion, to help improve the lives of patients by enhancing the critical medicines they depend on.

Responsibility —

ADVANZ PHARMA is committed to improving the lives of patients by enhancing the critical medicines they depend on. Partnerships are a fundamental part of this, and is vital to creating new, lasting relationships, where we can continue to invest significantly in products to help broaden patient access and health outcomes.

Our Partnerships —

ADVANZ PHARMA is committed to improving the lives of patients by enhancing the critical medicines they depend on. Partnerships are a fundamental part of this, and is vital to creating new, lasting relationships, where we can continue to invest significantly in products to help broaden patient access and health outcomes.

Investors —

Our goal is clear – to become the go to partner when commercialising complex medicines in European hospitals

We will do this by investing significantly in our portfolio through a combination of pipeline development and acquisition.

Latest News —

Image for ADVANZ PHARMA enters into agreement to acquire the rights to Eisai’s Zonegran® in the EU, Middle East, Russia and Australia

ADVANZ PHARMA enters into agreement to acquire the rights to Eisai’s Zonegran® in the EU, Middle East, Russia and Australia

Learn more
Image for Nordic Capital acquires speciality pharmaceutical company ADVANZ PHARMA in deal worth ~ $846 million

Press Releases — 01 Jun 2021

Nordic Capital acquires speciality pharmaceutical company ADVANZ PHARMA in deal worth ~ $846 million

Learn more
Image for Nordic Capital Acquires Specialty Pharmaceutical Company ADVANZ PHARMA in Deal Worth ~$846 Million

Press Releases — 01 Jun 2021

Nordic Capital Acquires Specialty Pharmaceutical Company ADVANZ PHARMA in Deal Worth ~$846 Million

Learn more
Image for ADVANZ PHARMA Corp. Limited Announces First Quarter 2021 Results

Press Releases — 14 May 2021

ADVANZ PHARMA Corp. Limited Announces First Quarter 2021 Results

Learn more
Image for ADVANZ PHARMA and Endo Announce Partnership for Paladin Labs to Commercialize Xydalba® (dalbavancin hydrochloride) in Canada

Press Releases — 13 Apr 2021

ADVANZ PHARMA and Endo Announce Partnership for Paladin Labs to Commercialize Xydalba® (dalbavancin hydrochloride) in Canada

Learn more
Image for ADVANZ PHARMA Corp. Limited Announces Fourth Quarter and 2020 Results

Press Releases — 17 Mar 2021

ADVANZ PHARMA Corp. Limited Announces Fourth Quarter and 2020 Results

Learn more